The Directory of Pharma Companies and News


Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, New Skin®, Dermoplast®, Domeboro®and Fiber Choice®. Kerasal Nail® (Emtrix®, Zanmira® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).
Category: Pharmaco
Category: Pharmaco

Moberg News

-0001-11-30Invitation - Presentation of Moberg Pharma's fourth quarter and full year results 2014
-0001-11-30Moberg Pharma launches innovative new Kerasal product in the U.S.
-0001-11-30Moberg Pharma announces issue of U.S. Patent related to MOB-015 for the treatment of Onychomycosis
-0001-11-30Moberg Pharma Extends Distribution Agreement with Menarini Group for Emtrix to Russia
-0001-11-30Moberg Pharma’s fungal nail product approved in China
-0001-11-30MOB-015 data to be presented at the 73rd Annual Meeting of the American Academy of Dermatology
-0001-11-30Moberg Pharma announces issue of U.S. Patent for Kerasal Nail
-0001-11-30Moberg Pharma announces grant of EU Patent for MOB-015 related to topical treatment of onychomycosis (nail fungus)
-0001-11-30Bulletin from Moberg Pharma’s Annual General meeting 2014
-0001-11-30Moberg Pharma AB (Publ) Delårsrapport januari – mars 2015
-0001-11-30Emtrix market leader in Malaysia with 45% market share
-0001-11-30Moberg Pharma expands Domeboro® retail presence with Walmart launch
-0001-11-30Notice of Annual General Meeting in Moberg Pharma AB (publ)
-0001-11-30Moberg Pharma Annual Report 2014
-0001-11-30Moberg Pharmas årsredovisning för 2014 offentliggjord
-0001-11-30Moberg Pharma AB (Publ) Bokslutskommuniké 2014
-0001-11-30Moberg Pharma AB (Publ) Year-end Report 2014
-0001-11-30Moberg Pharma acquires U.S OTC brand Balmex®
-0001-11-30Moberg Pharma AB (Publ) Interim report January – March 2015
-0001-11-30Moberg Pharma’s partner launches Kerasal Nail in China
-0001-11-30Moberg Pharma announces issue of European Patent for Kerasal Nail
-0001-11-30Moberg Pharma to receive Eurostars grant of EUR 0.9 million
-0001-11-30Change in number of shares and votes in Moberg Pharma
-0001-11-30Moberg Pharma AB Interim report January - June 2015
-0001-11-30Moberg Pharma and Colep enters Development agreement for late-stage development of MOB-015
-0001-11-30Moberg Pharma AB interim report January - September 2015
-0001-11-30Moberg Pharma regains rights to Emtrix® in certain EU markets
-0001-11-30Moberg Pharma’s Nomination Committee appointed
Brought to you by - Latest Jobs in Pharma
Brought to you by - Latest Jobs in Pharma.